Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) Director Sells 12,163 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips sold 12,163 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $6.39, for a total value of $77,721.57. Following the completion of the transaction, the director now directly owns 2 shares in the company, valued at $12.78. This trade represents a 99.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Joshua Phillips also recently made the following trade(s):

• On Friday, January 10th, Joshua Phillips sold 12,710 shares of Sera Prognostics stock. The stock was sold at an average price of $7.40, for a total value of $94,054.00.

Sera Prognostics Stock Performance

Shares of NASDAQ:SERA opened at $6.61 on Thursday. The business’s 50-day simple moving average is $7.44 and its 200 day simple moving average is $7.31. The company has a market cap of $223.23 million, a P/E ratio of -6.68 and a beta of 0.86. Sera Prognostics, Inc. has a one year low of $4.98 and a one year high of $12.35.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.09 million. During the same period last year, the business earned ($0.23) earnings per share. Analysts predict that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

A number of large investors have recently added to or reduced their stakes in the company. Quest Partners LLC lifted its holdings in Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after buying an additional 5,415 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Sera Prognostics during the third quarter worth about $78,000. The Manufacturers Life Insurance Company acquired a new position in shares of Sera Prognostics in the second quarter worth about $68,000. Prime Capital Investment Advisors LLC purchased a new position in Sera Prognostics in the third quarter valued at about $104,000. Finally, Pallas Capital Advisors LLC purchased a new position in Sera Prognostics in the fourth quarter valued at about $113,000. 54.64% of the stock is owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.